Kendler D L, Body J J, Brandi M L, Broady R, Cannata-Andia J, Cannata-Ortiz M J, El Maghraoui A, Guglielmi G, Hadji P, Pierroz D D, de Villiers T J, Ebeling P R, Rizzoli R
Department of Medicine, Division of Endocrinology, University of British Columbia, Vancouver, Canada.
CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium.
J Bone Oncol. 2021 Apr 23;28:100361. doi: 10.1016/j.jbo.2021.100361. eCollection 2021 Jun.
Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT.
In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture.
This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.
治疗进展减少了与造血干细胞移植（HSCT）相关的不良事件，并导致进行移植的数量增加。HSCT患者存活时间更长，同时对长期预后存在担忧。骨脆性和骨折是HSCT后长期发病的首要问题。
在HSCT受者中，已有证据支持对骨脆性进行更广泛监测以及对有骨质流失和/或骨折高风险的患者更合理地使用骨质疏松症药物治疗的建议。
本执行摘要报告并总结了先前发表的主要建议，包括骨评估、饮食和生活方式建议以及骨质疏松症药物治疗。
